Simultaneous HPLC–UV analysis of rufinamide, zonisamide, lamotrigine, oxcarbazepine monohydroxy derivative and felbamate in deproteinized plasma of patients with epilepsy

Contin, Manuela; Mohamed, Susan; Candela, Carmina; Albani, Fiorenzo; Riva, R.; Baruzzi, Agostino

doi:10.1016/j.jchromb.2009.11.039

Cited by 65 publications

(39 citation statements)

References 16 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…However, there is currently insufficient data to define a general therapeutic range for rufinamide [39]. Rufinamide serum or plasma concentrations can be determined by HPLC [145]. Monitoring of serum levels can be especially helpful in patients taking concomitant liver enzyme inducers or who are receiving hemodialysis.…”

Section: Rufinamidementioning

confidence: 99%

Therapeutic Drug Monitoring of the Newer Anti-Epilepsy Medications

Krasowski

2010

Pharmaceuticals

103

View full text Add to dashboard Cite

Abstract:In the past twenty years, 14 new antiepileptic drugs have been approved for use in the United States and/or Europe. These drugs are eslicarbazepine acetate, felbamate, gabapentin, lacosamide, lamotrigine, levetiracetam, oxcarbazepine, pregabalin, rufinamide, stiripentol, tiagabine, topiramate, vigabatrin and zonisamide. In general, the clinical utility of therapeutic drug monitoring has not been established in clinical trials for these new anticonvulsants, and clear guidelines for drug monitoring have yet to be defined. The antiepileptic drugs with the strongest justifications for drug monitoring are lamotrigine, oxcarbazepine, stiripentol, and zonisamide. Stiripentol and tiagabine are strongly protein bound and are candidates for free drug monitoring. Therapeutic drug monitoring has lower utility for gabapentin, pregabalin, and vigabatrin. Measurement of salivary drug concentrations has potential utility for therapeutic drug monitoring of lamotrigine, levetiracetam, and topiramate. Therapeutic drug monitoring of the new antiepileptic drugs will be discussed in managing patients with epilepsy.

show abstract

Section: Rufinamidementioning

confidence: 99%

Therapeutic Drug Monitoring of the Newer Anti-Epilepsy Medications

Krasowski

2010

Pharmaceuticals

103

View full text Add to dashboard Cite

show abstract

“…The determination of PHPLA, PHPAA and PHPA were mainly carried out by HPLC methods, such as HPLC-UV [20,21], HPLC with fluorescence detection (FLD) [22][23][24] and HPLC-MS [25][26][27]. Among them, the sensitivity of UV method is low, therefore the UV method is not suitable for the determination of trace amount of tyrosine metabolites in urine; MS method is sensitive, but the MS equipment is expensive [28][29][30].…”

Section: Introductionmentioning

confidence: 99%

Simultaneous determination of 4-hydroxyphenyl lactic acid, 4-hydroxyphenyl acetic acid, and 3,4-hydroxyphenyl propionic acid in human urine by ultra-high performance liquid chromatography with fluorescence detection

2017

View full text Add to dashboard Cite

A simple and reliable method was established for simultaneous determination of 4-hydroxyphenyl acetic acid, 4-hydroxyphenyl lactic acid, and 3,4-hydroxyphenyl propionic acid in human urine by high-performance liquid chromatography with fluorescence detection. Solid-phase extraction was used to eliminate the interferences in urine. The separation of three analytes was achieved using a C column and a mobile phase formed by a 95:5 v/v mixture of 50 mmol/L ammonium acetate buffer at pH 6.8 that contained 5 mmol/L tetrabutyl ammonium bromide and acetonitrile. Under the optimized conditions, the detection limits of 4-hydroxyphenyl acetic acid, 4-hydroxyphenyl lactic acid, and 3,4-hydroxyphenyl propionic acid were 4.8 × 10 , 8.80 × 10 , and 9.00 × 10 mg/L, respectively, and the recoveries were in the range of 85.0-120.0% with relative standard deviations of 1.5-3.1%. This method was used to analyze urine samples from breast cancer patients, healthy people and post-surgery breast cancer patients. Significant differences in urinary levels of 4-hydroxyphenyl acetic acid and 4-hydroxyphenyl lactic acid could be found between the breast cancer patients group and other two groups. No effect of age and sex was observed on the urinary levels of 4-hydroxyphenyl acetic acid and 4-hydroxyphenyl lactic acid. This method might be helpful for cancer biomarkers discovery in urine.

show abstract

“…Currently, a number of analytical methods for the monitoring of antiepileptic drugs in biological samples such as HPLC with UV detection , evaporative light‐scattering detection , fluorescence polarization immunoassay , and enzyme‐multiplied immunoassay technique have been reported but many suffer from disadvantages such as relatively long analytical run time, large sample volumes, and complex sample preparation. Various LC–MS‐based methods for one or several antiepileptic drugs have been developed and used in clinical laboratories but limited by the monitoring numbers of antiepileptic drugs or long run time which is not suitable for high‐throughput analysis.…”

Section: Introductionmentioning

confidence: 99%

Simultaneous determination of ten antiepileptic drugs in human plasma by liquid chromatography and tandem mass spectrometry with positive/negative ion‐switching electrospray ionization and its application in therapeutic drug monitoring

Yin

Wang

Shi

et al. 2016

J of Separation Science

View full text Add to dashboard Cite

A simple, rapid, and high-throughput liquid chromatography with tandem mass spectrometry method for the simultaneous quantitation of ten antiepileptic drugs in human plasma has been developed and validated. The method required only 10 μL of plasma. After simple protein precipitation using acetonitrile, the analytes and internal standard diphenhydramine were separated on a Zorbax SB-C18 column (50 × 4.6 mm, 2.7 μm) using acetonitrile/water as the mobile phase at a flow rate of 0.9 mL/min. The total run time was 6 min for each sample. The validation results of specificity, matrix effects, recovery, linearity, precision, and accuracy were satisfactory. The lower limit of quantification was 0.04 μg/mL for carbamazepine, 0.02 μg/mL for lamotrigine, 0.01 μg/mL for oxcarbazepine, 0.4 μg/mL for 10-hydroxycarbazepine, 0.1 μg/mL for carbamazepine-10,11-epoxide, 0.15 μg/mL for levetiracetam, 0.06 μg/mL for phenytoin, 0.3 μg/mL for valproic acid, 0.03 μg/mL for topiramate, and 0.15 μg/mL for phenobarbital. The intraday precision and interday precision were less than 7.6%, with the accuracy ranging between -8.1 and 7.9%. The method was successfully applied to therapeutic drug monitoring of 1237 patients with epilepsy after administration of standard antiepileptic drugs. The method has been proved to meet the high-throughput requirements in therapeutic drug monitoring.

show abstract

Simultaneous HPLC–UV analysis of rufinamide, zonisamide, lamotrigine, oxcarbazepine monohydroxy derivative and felbamate in deproteinized plasma of patients with epilepsy

Cited by 65 publications

References 16 publications

Therapeutic Drug Monitoring of the Newer Anti-Epilepsy Medications

Therapeutic Drug Monitoring of the Newer Anti-Epilepsy Medications

Simultaneous determination of 4-hydroxyphenyl lactic acid, 4-hydroxyphenyl acetic acid, and 3,4-hydroxyphenyl propionic acid in human urine by ultra-high performance liquid chromatography with fluorescence detection

Simultaneous determination of ten antiepileptic drugs in human plasma by liquid chromatography and tandem mass spectrometry with positive/negative ion‐switching electrospray ionization and its application in therapeutic drug monitoring

Contact Info

Product

Resources

About